4.6 Review

Atypical Antipsychotics for Acute Manic and Mixed Episodes in Children and Adolescents with Bipolar Disorder Efficacy and Tolerability

Journal

DRUGS
Volume 70, Issue 4, Pages 433-442

Publisher

ADIS INT LTD
DOI: 10.2165/11534540-000000000-00000

Keywords

-

Funding

  1. Abbott
  2. AstraZeneca
  3. Bristol-Myers Squibb
  4. Cephalon
  5. Eli Lilly
  6. GlaxoSmithKline
  7. Pfizer
  8. Repligen
  9. Wyeth
  10. AstraZeneca Pharmaceuticals
  11. National Institute of Mental Health
  12. National Alliance for Research in Schizophrenia and Depression
  13. NATIONAL INSTITUTE OF MENTAL HEALTH [K23MH085919, R01MH077047] Funding Source: NIH RePORTER

Ask authors/readers for more resources

The diagnosis of bipolar disorder (BD) in children is increasing, and often requires a comprehensive treatment plan to address a complex array of symptoms and associated morbidities. Pharmacotherapy, in combination with psychotherapeutic interventions, is essential for the treatment and stabilization of disrupted mood. Current evidence collectively demonstrates, by randomized controlled design, that atypical antipsychotics have efficacy for the treatment of acute manic or mixed symptoms in children and adolescents with BD. Additional longitudinal and biological studies are warranted to characterize the effects of atypical antipsychotics on all phases and stages of bipolar illness development in children and adolescents.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available